Search company, investor...

Cv Therapeutics

Stage

Acquired | Acquired

Total Raised

$20.91M

About Cv Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

Headquarters Location

3172 Porter Drive

Palo Alto, California, 94304,

United States

Loading...

Loading...

Cv Therapeutics Patents

Cv Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/22/2006

4/21/2009

Adenosine receptor antagonists, Xanthines, Neurological disorders, Purines, G protein coupled receptors

Grant

Application Date

8/22/2006

Grant Date

4/21/2009

Title

Related Topics

Adenosine receptor antagonists, Xanthines, Neurological disorders, Purines, G protein coupled receptors

Status

Grant

Latest Cv Therapeutics News

Innoforce Names Dewan Zeng CEO

Aug 3, 2023

Zeng previously served as lead for 20 clinical-stage assets at CV Therapeutics, Gilead, and Pfizer. 08.02.23 Zhejiang Innoforce Pharmaceuticals Co., Ltd., a CDMO that provides services for advanced therapy medicinal product (ATMP), appointed Dewan Zeng Chief Executive Officer, effective immediately. Yuling Li will continue to focus on technology innovation and CDMO operations as President. Zeng is an internationally recognized pharmaceutical product and business development leader. She has successfully leveraged her technical insights and leadership skills to foster organizational growth in several previous companies. Prior to joining Innoforce, Zeng was vice president, global head of search and evaluation, and business development at BeiGene, where she played a critical role in several transformative deals between BeiGene and other multi-national pharmaceutical companies. She was also a global program lead for over 20 clinical-stage assets at CV Therapeutics, Gilead, and Pfizer, where she was responsible for clinical and regulatory strategy and oversight of key clinical studies of those programs. She supported IND submission for twenty investigational products and NDA approval of three innovative products in the U.S., Europe, and China. "Innoforce was established with the vision to enable and accelerate the development and commercialization of innovative therapeutics,” said Guo-Liang Yu, Chairman of Innoforce. “With the enhancement of our leadership, we can now realize our vision at an accelerated pace. Dr. Zeng brings broad global experiences in high-performing pharmaceutical companies. I am confident in her ability to lead Innoforce through the next chapter." Zeng said, "I am thrilled to be joining Innoforce and am inspired by its strategy to become a leader in process development and manufacturing of ATMPs; I look forward to working with our leadership team and our partners to bring more effective medicines to patients around the world."

Cv Therapeutics Frequently Asked Questions (FAQ)

  • Where is Cv Therapeutics's headquarters?

    Cv Therapeutics's headquarters is located at 3172 Porter Drive, Palo Alto.

  • What is Cv Therapeutics's latest funding round?

    Cv Therapeutics's latest funding round is Acquired.

  • How much did Cv Therapeutics raise?

    Cv Therapeutics raised a total of $20.91M.

  • Who are the investors of Cv Therapeutics?

    Investors of Cv Therapeutics include Gilead Sciences, Alloy Ventures, Asset Management Ventures and Frazier Healthcare Partners.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.